« Back
Home /
Exendin-4

Exendin-4

Item no.	HY-13443-25mg
Manufacturer	MedChem Express
CASRN	141758-74-9
Amount	25 mg
Quantity options	100 mg 10 mMx1 mL 10 mg 1 mg 25 mg 50 mg 5 mg
Category	Oncology Metabolism Diabetes Glucose Homeostasis Cholesterol & Lipid Metabolism Regulation of Appetite Enzymes Other Fatty Acid Enzymes Inhibitors & Compound Libraries Small Molecules By Organ Breast Cancer
Type	Inhibitors
Specific against	other
Purity	99.95
Citations	[1]Doyle ME, et al. The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity. Regul Pept. 2003 Jul 15;114(2-3):153-8.\|[2]Wei R, et al. Exenatide exerts direct protective effects on endothelial cells through the AMPK/Akt/eNOS pathway in a GLP-1 receptor-dependent manner. Am J Physiol Endocrinol Metab. 2016 Jun 1;310(11):E947-57.\|[3]Fidan-YaylalI G, et al. Antidiabetic exendin-4 activates apoptotic pathway and inhibits growth of breast cancer cells. Tumour Biol. 2016 Feb;37(2):2647-53.\|[4]Ding X, et al. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/obmice. Hepatology. 2006 Jan;43(1):173-81.\|[5]Nachnani JS, et al. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia. 2010 Jan;53(1):153-9.\|[6]Selley E, et al. Exenatide induces aortic vasodilation increasing hydrogen sulphide, carbon monoxide and nitric oxide production. Cardiovasc Diabetol. 2014 Apr 2;13:69. Acta Biochim Biophys Sin (Shanghai). 2017 Jul 1;49(7):573-580.\|Am J Physiol Cell Physiol. 2024 May 13.\|Am J Physiol Endocrinol Metab. 2020 Dec 1;319(6):E1019-E1030.\|Annals of the Romanian Society for Cell Biology. 2021 Mar 15.\|Asian J Pharm Sci. 2024 Mar 12, 100904.\|Biochim Biophys Acta Mol Cell Res. 2022 May 27;1869(9):119300.\|Biomacromolecules. 2024 Jul 1.\|Biomedicines. 2020 Nov 9;8(11):485.\|bioRxiv. 2020 Jul.\|bioRxiv. 2024 August 10.\|bioRxiv. 2024 Mar 20.\|bioRxiv. 2024 May 3.\|bioRxiv. 2024 May 8.\|BMC Biol. 2021 Mar 3;19(1):40.\|Br J Pharmacol. 2020 Aug;177(15):3389-3402. \|Br J Pharmacol. 2024 May 28.\|Br J Pharmacol. 2024 Sep 26.\|Chem Biol Interact. 2019 May 1;304:186-193.\|Drug Deliv. 2022 Dec;29(1):548-560.\|Eur J Pharmacol. 2024 Nov 6:985:177106.\|Eur J Pharmacol. 2024 Oct 2:177029.\|Exp Cell Res. 2023 Jan 7;113469.\|Front Behav Neurosci. 05 January 2022.\|Front Pharmacol. 2019 Oct 25;10:1230.\|Front Pharmacol. 2021 Jul 19;12:694476.\|Gerontology. 2023 Mar 7;1-12.\|Gut. 2022 Jun 13;gutjnl-2021-326541.\|Inflamm Res. 2024 May 15.\|Insects. 2024 Jul 5.\|Int Immunopharmacol. 2021 Jan;90:107192.\|Int Immunopharmacol. 2023 May 19;120:110339.\|Int Immunopharmacol. 2024 Aug 1:140:112844.\|Int J Biol Sci. 2022; 18(4): 1328-1346.\|Int J Nanomedicine. 2025 Mar 17:20:3363-3378.\|J Adv Res. 2025 Mar 10:S2090-1232(25)00174-2.\|J Biol Chem. 2018 Nov 23;293(47):18086-18098. \|J Cell Physiol. 2021 May;236(5):3641-3659.\|J Diabetes Res. 2019 Dec 9;2019:8905917.\|J Funct Foods. 2023 Aug, 107, 105706.\|J Invest Dermatol. 2021 Oct 20;S0022-202X(21)02369-1.\|J Neuroinflammation. 2019 Nov 28;16(1):242.\|medRxiv. 2024 Jul 23.\|Mol Med. 2024 May 8;30(1):58.\|Mol Metab. 2023 Sep 26, 101811.\|Nature. 2025 Mar 5.\|Neural Regen Res. 2022.\|Neurogastroenterol Motil. 2019 Feb;31(2):e13482.\|Res Sq. 2024 Aug 11.\|Sci Rep. 2017 Jun 28;7(1):4351.\|Sci Rep. 2024 Jun 14;14(1):13726.\|SSRN. 2019 Jun 27.\|Structure. 2022 Feb 2;S0969-2126(22)00006-5.\|Biomaterials. 2021 Aug;275:120944.
Smiles	O=C(NCC(N[C@@H](CCC(O)=O)C(NCC(N[C@@H]([C@H](O)C)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H]([C@H](O)C)C(N[C@@H](CO)C(N[C@@H](CC(O)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CO)C(N[C@@H](CCCCN)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCSC)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](C)C(N[C@@H](C(C)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(C)C)C(N[C@@H](CC2=CC=CC=C2)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC3=CNC4=CC=CC=C34)C(N[C@@H](CC(C)C)C(N[C@@H](CCCCN)C(N[C@@H](CC(N)=O)C(NCC(NCC(N5[C@@H](CCC5)C(N[C@@H](CO)C(N[C@@H](CO)C(NCC(N[C@@H](C)C(N6[C@@H](CCC6)C(N7[C@@H](CCC7)C(N8[C@@H](CCC8)C(N[C@@H](CO)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC9=CNC=N9)N
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Exenatide
Shipping Condition	Cool pack
Available
Manufacturer - Type	Peptides
Manufacturer - Applications	Metabolism-sugar/lipid metabolism
Manufacturer - Targets	GCGR
Shipping Temperature	Blue Ice
Storage Conditions	-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)
Molecular Weight	4186.57
Product Description	Exendin-4 (Exenatide), a 39 amino acid peptide, is a long-acting glucagon-like peptide-1 receptor agonist with an IC50 of 3.22 nM.
Manufacturer - Research Area	Metabolic Disease; Cardiovascular Disease; Cancer
Solubility	DMSO: ≥ 32 mg/mL\|Ethanol: < 1 mg/mL (ultrasonic; warming; heat to 60°C)\|H2O: 33.33 mg/mL (ultrasonic)
Manufacturer - Pathway	GPCR/G Protein
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-13443-25mg-safety-datasheet.pdf